Education
About Us
Working with TipRanks
Follow Us
Oncology Institute, Inc. (TOI)
NASDAQ:TOI
Earnings Data
Report Date
Aug 12, 2025TBA Not Confirmed
Period Ending
2025 (Q2)Consensus EPS Forecast
-0.09Last Year’s EPS
-0.17Same Quarter Last Year
Moderate Buy
Based on 1 Analysts Ratings
Earnings Call Summary
Earnings Call Date:May 14, 2025
|% Change Since: 17.72%
|Next Earnings Date:Aug 12, 2025
Earnings Call Sentiment|Positive
The earnings call presented a strong start to 2025 with significant revenue growth and improvements in dispensary segment performance, gross profit, and SG&A reduction. However, challenges remain with adjusted EBITDA loss, net loss, and the revenue impact from outsourcing the clinical trials program. Despite these challenges, the overall trajectory and strategic initiatives indicate a focus on future profitability.Company Guidance
In the first quarter of 2025, The Oncology Institute reported a 10% increase in revenue compared to the same period in the previous year, with total revenue reaching $104.4 million. The company's retail Pharmacy and Dispensary business significantly contributed to this growth, generating $49.3 million in revenue and over $9 million in gross profit, representing a 20% year-over-year increase. The fee-for-service business also saw growth, with a 9% increase quarter-over-quarter and a 2% increase year-over-year. Additionally, the company signed new capitated contracts in Florida, California, and Nevada, adding over 80,000 lives and projecting approximately $50 million in new annualized revenue. The company reported an adjusted EBITDA loss of $5.1 million, aligning with the upper end of their guidance, and achieved a gross profit of $17.2 million, a 44.1% increase from the previous year. The company anticipates continuing this positive trajectory towards profitability and cash flow positivity by the end of 2025, supported by strategic market expansions and operational efficiencies.Revenue Growth
Revenue for Q1 2025 increased by 10% versus the prior year period, reaching $104.4 million.
Dispensary Segment Performance
The Dispensary segment grew by 24.2%, contributing $49.3 million in revenue and over $9 million in gross profit in Q1.
Capitated Contract Wins
New capitated contract wins added over 80,000 lives in the first quarter with projected new revenue of approximately $50 million on an annualized basis.
Gross Profit Improvement
Gross profit in Q1 of 2025 was $17.2 million, an increase of 44.1% compared to Q1 of 2024.
SG&A Reduction
SG&A, including depreciation and amortization, was $27.2 million in Q1 of 2025, a 9% decline compared to Q1 of 2024.
Debt Reduction and Capital Raise
Executed a partial paydown of convertible preferred debt of $20 million and a capital raise that added $16 million back to the balance sheet.
TOI Earnings History
The table shows recent earnings report dates and whether the forecast was beat or missed. See the change in forecast and EPS from the previous year.
Beat
Missed
TOI Earnings-Related Price Changes
Report Date | Price 1 Day Before | Price 1 Day After | Percentage Change |
|---|---|---|---|
May 14, 2025 | $2.37 | $3.04 | +28.27% |
Mar 24, 2025 | $1.00 | $1.24 | +24.00% |
Nov 13, 2024 | $0.26 | $0.24 | -7.69% |
Aug 13, 2024 | $0.55 | $0.45 | -18.18% |
Earnings announcements can affect a stock’s price. This table shows the stock's price the day before and the day after recent earnings reports, including the percentage change.
FAQ
When does Oncology Institute, Inc. (TOI) report earnings?
Oncology Institute, Inc. (TOI) is schdueled to report earning on Aug 12, 2025, TBA Not Confirmed.
What is Oncology Institute, Inc. (TOI) earnings time?
Oncology Institute, Inc. (TOI) earnings time is at Aug 12, 2025, TBA Not Confirmed.
Where can I see when companies are reporting earnings?
You can see which companies are reporting today on our designated earnings calendar.
What companies are reporting earnings today?
You can see a list of the companies which are reporting today on TipRanks earnings calendar.
What is TOI EPS forecast?
TOI EPS forecast for the fiscal quarter 2025 (Q2) is -0.09.